These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19016380)

  • 1. Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection.
    Childers ME; Woods SP; Letendre S; McCutchan JA; Rosario D; Grant I; Mindt MR; Ellis RJ;
    J Neurovirol; 2008 Nov; 14(6):550-7. PubMed ID: 19016380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.
    Christo PP; Greco DB; Aleixo AW; Livramento JA
    BMC Infect Dis; 2007 Dec; 7():147. PubMed ID: 18096083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.
    Papasavvas E; Kostman JR; Mounzer K; Grant RM; Gross R; Gallo C; Azzoni L; Foulkes A; Thiel B; Pistilli M; Mackiewicz A; Shull J; Montaner LJ
    PLoS Med; 2004 Dec; 1(3):e64. PubMed ID: 15630469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.
    Touloumi G; Pantazis N; Stirnadel HA; Walker AS; Boufassa F; Vanhems P; Porter K;
    J Acquir Immune Defic Syndr; 2008 Dec; 49(5):492-8. PubMed ID: 18989233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
    Darwich L; Esteve A; Ruiz L; Paredes R; Bellido R; Cabrera C; Romeu J; Bofill M; Clotet B; Martinez-Picado J
    AIDS Res Hum Retroviruses; 2008 May; 24(5):725-32. PubMed ID: 18462084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].
    Pavie J; Porcher R; Fournier S; André F; Tournoux C; Palmer P; Rabian C; Jean-Michel M
    Presse Med; 2005 Jun; 34(10 Suppl):1S8-13. PubMed ID: 16025661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women.
    Cohen RA; Boland R; Paul R; Tashima KT; Schoenbaum EE; Celentano DD; Schuman P; Smith DK; Carpenter CC
    AIDS; 2001 Feb; 15(3):341-5. PubMed ID: 11273214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).
    Oyomopito R; Lee MP; Phanuphak P; Lim PL; Ditangco R; Zhou J; Sirisanthana T; Chen YM; Pujari S; Kumarasamy N; Sungkanuparph S; Lee CK; Kamarulzaman A; Oka S; Zhang FJ; Mean CV; Merati T; Tau G; Smith J; Li PC;
    HIV Med; 2010 Sep; 11(8):519-29. PubMed ID: 20345881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
    Kousignian I; Abgrall S; Duval X; Descamps D; Matheron S; Costagliola D;
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):50-7. PubMed ID: 14501793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
    Bogoch II; Davis BT; Venna N
    J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.
    Gibb DM; Duong T; Leclezio VA; Walker AS; Verweel G; Dunn DT;
    Pediatr Infect Dis J; 2004 May; 23(5):446-50. PubMed ID: 15131469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.
    Sevigny JJ; Albert SM; McDermott MP; McArthur JC; Sacktor N; Conant K; Schifitto G; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Epstein LG; Marder K
    Neurology; 2004 Dec; 63(11):2084-90. PubMed ID: 15596754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.